• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024

    4/19/24 4:05:00 PM ET
    $OLK
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OLK alert in real time by email

    UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the "AGM") of Olink Holding AB (publ), reg. no 559189-7755, (the "Company"), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com.

    Adoption of the balance sheet and income statement, disposition regarding the Company's results and discharge from liability

    The AGM adopted the Company's income statement and balance sheet and the consolidated income statement and consolidated balance sheet.

    The AGM resolved to dispose the Company's results in accordance with the Board of Directors' proposal, whereby no dividend will be paid for the financial year 2023 and that the Company's available funds be capitalized in a new account.

    The AGM also discharged the Board Members and the CEO from liability for the financial year 2023.

    Remuneration to the Board of Directors and Auditor

    The AGM decided, in accordance with the Nomination Committee's proposal, that the remuneration to the Board of Directors shall be distributed as follows: USD 120,000 to the Chair of the Board of Directors, USD 70,000 to each of the other Board Members appointed by the AGM who are not employed by the Company, additionally USD 20,000 to the Chair of the Remuneration Committee and additionally USD 10,000 to each other member of the Remuneration Committee, additionally USD 30,000 to the Chair of the Audit Committee and additionally USD 15,000 to each other member of the Audit Committee. Tommi Unkuri shall not receive any fees for Board or Committee work. Total fees amount to USD 640,000.

    The AGM decided that remuneration to the Auditor shall be paid according to approved invoices.

    Election of board members

    The AGM resolved, in accordance with the Nomination Committee's proposal, that the Board of Directors shall consist of nine Board Members and one Deputy Board Member. For the period until the end of the next Annual General Meeting the AGM re-elected the present Board Members Jon Hindar, Jon Heimer, Solange Bullukian, Johan Lund, Nicolas Roelofs, Mary Reumuth, Robert Schueren, Dr. Gregory J. Moore and Tommi Unkuri. Furthermore, it was resolved to re-elect Jon Hindar as Chair of the Board of Directors.

    The AGM resolved, in accordance with the Nomination Committee's proposal, to re-elect Johan Pietilä Holmner as Deputy Board Member.

    Election of auditor

    The AGM resolved, in accordance with the Nomination Committee's proposal, to elect the registered audit firm Ernst & Young AB as auditor for the period until the end of the next Annual General Meeting. Ernst & Young AB has informed that Fredrik Norrman will be appointed as auditor in charge.

    Resolution on incentive program LTI I 2024 and issue of warrants and restricted stock units

    The AGM resolved not to approve the Majority Shareholders' proposal to adopt an additional Long Term Incentive program for the Board Members of the Company ("LTI I 2024").

    Resolution on incentive program LTI II 2024 and issue of warrants and restricted stock units

    The AGM resolved, in accordance with the Board of Directors' proposal, to adopt an additional Long Term Incentive program for the members of the group management, key employees, other employees and consultants of the Company and within the group ("LTI II 2024").

    LTI II 2024 consists of restricted stock units (with warrants as hedging arrangement). Upon exercise of all warrants issued within the frame of LTI II 2024 up to 849,195 shares (with reservation for any re-calculation) may be issued, equivalent to a maximum dilution of approximately 0.68 percent of the shares and votes of the Company. Upon full exercise of the warrants, the Company's share capital will increase with SEK 2,065,162.94.

    The calculations above have been based on the number of shares and votes in the Company as of the date of the notice.

    Authorization for the Board of Directors to decide on a new issue

    The AGM resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors, on one or several occasions until the next Annual General Meeting to resolve on issues of new shares, and that such new issue can be performed with deviation from the shareholders' preferential rights. The authorization may only be utilized to the extent that it corresponds to a dilution of not more than 20 percent of the total number of shares based on the number of shares outstanding at the time of the 2024 Annual General Meeting. Payment shall be able to be made in cash, in kind, by offset or otherwise in accordance with other conditions.

    For more information please contact:

    IR Contact

    David Deuchler, CFA

    Gilmartin Group

    [email protected]

    Media Contact

    Michael B. Gonzales

    VP Global Marketing

    Mobile: + 1 415 308 6467

    [email protected]



    Primary Logo

    Get the next $OLK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OLK

    DatePrice TargetRatingAnalyst
    1/5/2023$27.00Sector Outperform
    Scotiabank
    12/14/2022$28.00Buy
    Canaccord Genuity
    2/14/2022$33.00 → $32.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $OLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notice to attend the Extra General Meeting of Olink Holding AB (publ)

      This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. UPPSALA, Sweden, July 11, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the "Company"), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.m. CEST on Tuesday 6 August 2024, in the Company's facilities at Salagatan 16F, Uppsala. Registration for the meeting commences at 3:30 p.m. CEST. NOTICE OF PARTICIPATION Shareholders who wish to attend in the proceedings of the Extra General Meeting must: be entered in the share register kept on behalf of the Company by Eur

      7/11/24 4:05:45 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period

      Subsequent Offering Period Scheduled to Expire at 5:00 p.m., New York Time, on July 16, 2024 Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) ("Olink") (NASDAQ:OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment. "We are excited to welcome Olink colleagues to Thermo Fisher," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "Protein research

      7/10/24 8:00:00 AM ET
      $OLK
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components
    • Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher

      UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced that the UK Competition and Markets Authority (the "CMA") has unconditionally approved the previously announced tender offer (the "Offer") by Orion Acquisition AB (the "Buyer"), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher" or "Parent"), for all outstanding Common Shares and American Depositary Shares (together, the "Shares") of Olink for $26.00 per Share. The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink. As a result of the CMA approval, Olink and Thermo Fis

      7/8/24 7:37:45 AM ET
      $OLK
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components